E Fund Management’s Sutro Biopharma STRO Stock Holding History

E Fund Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,225	Closed	-$57K	–	335
2023 Q1	$57K	Buy	+1,225	New	+$77.7K	﹤0.01%	331

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

E Fund Management's STRO Position: Q2 2023 in Review

E Fund Management sold out of Sutro Biopharma (STRO) in Q2 2023, closing a stake of 1,225 shares — an estimated $57K sold.

E Fund Management first reported a position in STRO in Q1 2023 and held it in 1 quarter. The position peaked at $57K in Q1 2023. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

E Fund Management reported no remaining Sutro Biopharma position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 1,225 Sutro Biopharma shares in Q2 2023, an estimated $57K.
E Fund Management first reported a position in Sutro Biopharma in Q1 2023 and held it in 1 quarter.
E Fund Management's Sutro Biopharma position peaked at $57K in Q1 2023.
120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.